Mild asthma patients may not need daily inhaled steroid therapy: study
For two decades, asthma treatment for millions of people with a milder form of the disease has consisted of daily inhaled steroid medicine to reduce inflammation. Now, a new study has found that asthmatics who take the low-dose medication as a daily routine do no better than those who turn to their inhalers only when they have symptoms.
The findings suggest a different, personalized, and far less expensive approach to treating the common inflammatory condition, according to the researchers.
The report will be published in The Journal of the American Medical Association on September 12, 2012.
In effect, the study challenges national and international guidelines that have been in place for 20 years. According to those recommendations, if a person's asthma is mild but persistent, he or she should take an inhaled steroid every day to suppress airway inflammation and reduce the risk of exacerbations.
Mild persistent asthma is one of four types of the disease, which affects as many as one in every 12 people in the United States, according to federal statistics.
"Daily treatment with an inhaled corticosteroid has long been believed to be the best treatment for mild persistent asthma, but it is not followed by the majority of patients,'' said senior author Homer A. Boushey, MD, a UCSF professor of medicine in the division of Pulmonary and Critical Care Medicine. A pioneer in the field who has been involved in asthma research for 40 years, Boushey served on the expert committee that developed the current National Institutes of Health's guidelines for managing the disease.
"People don't seem to like taking this type of treatment every day – just a third of the inhaler prescriptions are renewed even once,'' Boushey said. "So we wondered what would happen if people with mild asthma already well controlled by daily treatment with an inhaled corticosteroid instead took a puff only when they used their rescue medication – usually albuterol—for relief of symptoms.''
This video is not supported by your browser at this time.
Dr. William J. Calhoun discusses how these findings may change treatment guidelinesThe upshot: patients who took inhaled corticosteroid only when they had symptoms wound up using half as much of the medication but did not have more severe symptoms. Nor did they miss more days of work or school, or have more flare-ups.
Called the Best Adjustment Strategy for Asthma in the Longer Term trial (BASALT), the study involved a randomized, double-blinded, placebo-controlled trial conducted by the Asthma Clinical Research Network at 10 academic medical centers across the country including UCSF and the University of Texas Medical Branch.
Altogether, 342 adults with mild to moderate, persistent asthma took part in the study over nine months between 2007 and 2010. All were diagnosed by physicians and all had either reversible airflow limitation or airway hyperresponsiveness. In each case, the participant's asthma was under control due to low-dose inhaled corticosteroids.
The scientists in the study evaluated three different approaches to the use of inhaled corticosteroids:
- Inhaler assessments and dosage adjustments made every six weeks by a physician;
- Inhaler adjustments made every six weeks based on measurements of exhaled nitric oxide, a marker of inflammation of the airwaves;
- Inhaler usage adjusted by participants based on their day-to-day symptoms – this consisted of taking one puff of their inhaled corticosteroid for every puff of an albuterol inhaler taken "as needed'' for relief of symptoms.
"The goal of our study was to compare different approaches to adjusting inhaled corticosteroid treatment on the frequency and severity of asthma attacks and on quality of life,'' Boushey said. "This is not a treatment breakthrough but it may possibly open the door to a new approach to treatment, and it will certainly be considered by the expert panel for the NIH's guidelines for asthma treatment.
"This approach allows personalization of treatment and is easy for patients. Also, it could hypothetically result in saving $2 billion a year in medication costs,'' Boushey said.
UCSF co-authors are John V. Fahy, MD, a professor of pulmonary medicine, and Stephen C. Lazarus, MD, a professor of clinical medicine. The lead authors are William J. Calhoun, MD, and Bill T. Ameredes, PhD, of the University of Texas Medical Branch.
"This is a step forward in asthma management,'' Calhoun said. "It enables patients to use their steroids only when they have symptoms. It is 'temporal personalization,' adjusting medication on a day to day basis.''
Asthma has been on the upswing for much of the last century, and is now one of the most common diseases in the world, affecting approximately 300 million people globally including an estimated 24 million people in the U.S., according to the federal Centers for Disease Control and Infection.
More prevalent in western, developed countries, the condition varies in its severity – some people are affected daily, others seasonally or episodically. Asthma is classified into four types based on severity: intermittent, mild persistent, moderate persistent, and severe persistent.
Journal reference: Journal of the American Medical Association
Provided by University of California, San Francisco
- Inhaled steroids may not be enough for some children with asthma May 22, 2007 | not rated yet | 0
- Children taking steroids for asthma are slightly shorter than peers Sep 03, 2012 | not rated yet | 0
- Baseline characteristics of children with mild persistent asthma predict response to inhaled corticosteroid May 22, 2012 | not rated yet | 0
- Treatment for mild asthma leads to improved lung function Mar 10, 2008 | not rated yet | 0
- A large subgroup of mild-to-moderate asthma is persistently non-eosinophilic Jan 06, 2012 | not rated yet | 0
- Motion perception revisited: High Phi effect challenges established motion perception assumptions Apr 23, 2013 | 3 / 5 (2) | 2
- Anything you can do I can do better: Neuromolecular foundations of the superiority illusion (Update) Apr 02, 2013 | 4.5 / 5 (11) | 5
- The visual system as economist: Neural resource allocation in visual adaptation Mar 30, 2013 | 5 / 5 (2) | 9
- Separate lives: Neuronal and organismal lifespans decoupled Mar 27, 2013 | 4.9 / 5 (8) | 0
- Sizing things up: The evolutionary neurobiology of scale invariance Feb 28, 2013 | 4.8 / 5 (10) | 14
Find a link between physics and assignment problems
1 hour ago Hi ! I've been working about assignments problems and how to solve them. I will have to do a presentation about it in few weeks. However, I'll...
Light as a source of electricity
1 hour ago Hello Dear Fellows! We all know that light is an electromagnetic wave and also we know that an antenna receives EM waves and...
A question about the energy stored in a capacitor.
1 hour ago If we imagine a simple circuit with a battery and a capacitor with negligible internal resistance, the capacitor is charged up to a point where the...
Electric field-Charge inside a metallic shell
4 hours ago I am having few doubts while studying electric field which i am putting here Suppose there is a spherical metallic shell with point charge q1 at...
Change in momentum when a body is thrown up and falls back down.
10 hours ago Say, a body of mass 'm' is thrown at a certain angle with the vertical with certain initial velocity 'u'. The initial momentum of this object is mu....
change in speed and wavelength of light while travelling from one med
10 hours ago what is the mechanism by which light changes its speed and wavelength while travelling from one medium to other. I know it is c/n or lamda/n and know...
- More from Physics Forums - Classical Physics
More news stories
(Medical Xpress)—Inflammation is an important response in the body - it helps you to kill off invaders such bacteria that could cause a harmful infection. But if it's chronic or uncontrolled, inflammation can also cause ...
Inflammatory disorders May 14, 2013 | not rated yet | 0 |
New research by medical students working in the Breathe Well Centre of Research Excellence at the UTAS School of Medicine has revealed swimming has health benefits for young people with asthma, with no adverse effects on ...
Inflammatory disorders May 10, 2013 | not rated yet | 0
An estimated 4,837,000 asthmatics with allergic bronchopulmonary aspergillosis (ABPA) could benefit substantially from antifungal treatment, say researchers from The University of Manchester and the University of Toronto.
Inflammatory disorders May 08, 2013 | not rated yet | 0
Type 1 (insulin-dependent) diabetes appears to increase the risk of heart disease, the leading cause of death among people with high blood sugar, partly by stimulating the production of calprotectin, a protein that sparks ...
Inflammatory disorders May 07, 2013 | 4.5 / 5 (2) | 0 |
Researchers at the University of Wisconsin have identified a potential new risk factor for obstructive sleep apnea: asthma. Using data from the National Institutes of Health (Heart, Lung, and Blood Institute)-funded Wisconsin ...
51 minutes ago | not rated yet | 0 |
Gourmands and foodies everywhere have long recognized ginger as a great way to add a little peppery zing to both sweet and savory dishes; now, a study from researchers at Columbia University shows purified components of the ...
50 minutes ago | not rated yet | 0
A new study looking at sleep-disordered breathing (SDB) and markers for Alzheimer's disease (AD) risk in cerebrospinal fluid (CSF) and neuroimaging adds to the growing body of research linking the two.
1 hour ago | not rated yet | 0 |
In their quest to learn more about the variability of cells between and within tissues, biomedical scientists have devised tools capable of simultaneously measuring dozens of characteristics of individual ...
1 hour ago | 5 / 5 (1) | 0 |
Scientists at Johns Hopkins have turned their view of osteoarthritis (OA) inside out. Literally. Instead of seeing the painful degenerative disease as a problem primarily of the cartilage that cushions joints, ...
1 hour ago | 5 / 5 (1) | 0 |
The hunt for an HIV vaccine has gobbled up $8 billion in the past decade, and the failure of the most recent efficacy trial has delivered yet another setback to 26 years of efforts.
5 hours ago | not rated yet | 0